| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 127.3 | 97.8 |
| Profit before tax | 80.1 | 48.0 |
| Net income | 63.1 | 79.4 |
| EPS (diluted, $ a share) | $2.05 | $2.66 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -20.5% |
|---|---|
| Revenue, year on year | +30.2% |
| Operating margin | 55.9% |
10-Q filed with the SEC, NASDAQ: KRYS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Krystal Biotech, Inc.: key numbers
- Share price
- $297.90Close, Nov 16
- Market cap
- $8.83B
- Shares outstanding
- 29.63MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Krystal Biotech, Inc.
All →Krystal Biotech Earnings Call: Key Takeaways
Krystal Biotech delivered strong Q3 revenue growth of 30% and profitability, though clinical timelines for several pipeline programs were pushed to 2027, prompting a $400 million share repurchase authorization.
- Call
- Nov 2, 2026, 8:30 AM ET
Krystal Biotech Financial Results
Krystal Biotech reported third quarter 2026 financial results, highlighted by $127.3 million in global VYJUVEK net product revenue, a 30% year-over-year increase. The company ended the quarter with a strong cash position of $1.2 billion and announced a new $400 million share repurchase program. Additionally, the company completed pricing negotiations for VYJUVEK in Germany and Italy and reported positive clinical data for its KB113 candidate in Gorlin syndrome.
“Continued growth in VYJUVEK revenue is supporting profitability and funding the advancement of our pipeline. Our financial strength allows us to invest fully in these programs and our global commercial expansion while returning capital to shareholders. The $400 million share repurchase program, under which we expect to repurchase shares opportunistically over the next two years, reflects our confidence in Krystal’s long-term growth prospects and our commitment to disciplined capital allocation.”
Krish S. Krishnan, Chairman and Chief Executive Officer
Krystal Biotech Clinical Trial Data
Krystal Biotech announced positive proof-of-concept clinical data from its Gorlin Syndrome Pilot Study evaluating KB113 for the treatment of basal cell carcinomas. The study showed that over 80% of assessed lesions regressed across three patients, including non-injected lesions, suggesting a systemic abscopal effect.